COMMUNIQUÉS West-GlobeNewswire

-
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
27/09/2024 -
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
27/09/2024 -
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
27/09/2024 -
33 Medical Wins 2024 Best Technology in Spine Award for Innovative NuvoDisc® Device
27/09/2024 -
WeightWatchers Announces Executive Leadership Transition
27/09/2024 -
ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
27/09/2024 -
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
27/09/2024 -
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
27/09/2024 -
Venus Concept Announces $15 million Debt-to-Equity Exchange Transaction
27/09/2024 -
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
27/09/2024 -
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
27/09/2024 -
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
27/09/2024 -
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines
27/09/2024 -
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
27/09/2024 -
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
27/09/2024 -
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
27/09/2024 -
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
27/09/2024 -
Nexstim Receives Order for NBS System 5 in Finland
27/09/2024 -
Information on the total number of voting rights and shares
27/09/2024
Pages